Sylentis will perform the initial clinical trial on its own in Spain for logistical reasons, but expects to later test the topically administered drug in other countries, including the US, according to a company official.
The grants will help pay for research into the function of conserved miRNAs in plants, the role the non-coding RNAs play in human T- and B-cell activation, the impact of miRNAs in brain cancer, and how miRNAs affect the aging process.
The settlement terminates a licensing agreement signed between Rockefeller and Ligand in 1992 related to patents and know-how surrounding peptidyl hormone-mediated gene expression technology discovered primarily by a Rockefeller scientist.
Life Technologies, Max Planck Institute for Evolutionary Anthropology, 454 Life Sciences, Applied Biosystems, Baylor College of Medicine, University of Bristol, University of Liverpool, John Innes Centre, Helicos BioSciences, Febit, and more…
Researchers from the Netherlands have uncovered a new gene expression signature linked to ovarian cancer survival that is providing hints about potential pathways of importance for the disease. But authors warn that using such signatures for guiding treatment may be a ways off.
Affy aims to target downstream genomic-analysis markets with the products gained through its acquisitions of Panomics and True Materials last year, roll out new genotyping assays on its GeneTitan array platform, and consolidate its manufacturing facilities.
The activities are part of Kreatech's makeover from a biotech specializing in FISH probes and labeling kits, to a molecular diagnostics company with expertise in oncology, hematology, and constitutional disorders.